Movement Alert｜InnoCare Pharma Falls 5.04% in Regular Trading, Biotech Sector Sell-Off Compounds Post-Catalyst Profit-Taking

Market Focus07-17 10:55

On July 17, InnoCare Pharma declined 5.04% in regular trading, trading at HK$13.88/share, with turnover of HK$85.67 million.

The decline comes as the broader biotechnology sector experienced a sharp systematic sell-off, with AKESO down 12.28%, 3SBIO down 12.17%, SKB BIO down 6.83%, INNOVENT BIO down 5.94%, and BEIGENE down 2.57%. On the company front, InnoCare had disclosed back-to-back positive clinical results on July 15 and July 16 — its TYK2 inhibitor soficitinib achieved the primary endpoint in a Phase III registrational trial for moderate-to-severe atopic dermatitis, and subsequently met the primary endpoint in a Phase II study for non-segmental vitiligo. However, with positive catalysts already absorbed by the market, short-term profit-taking pressures emerged alongside the sector-wide pullback, driving the stock lower.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment